Health and Healthcare
Will Gilead Sciences Earnings Get a Boost From a Collaboration?
Published:
Last Updated:
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive
compensation for actions taken through them.
Gilead Sciences Inc. (NASDAQ: GILD) is set to report its most recent quarterly results after the markets close on Tuesday. The consensus estimates are $1.67 in earnings per share (EPS) on $5.4 billion in revenue. In the first quarter of last year, the biotech giant said it had EPS of $2.23 and $6.5 billion in revenue.
Back in February, Gilead announced the collaboration of its subsidiary Kite Pharma with Sangamo Therapeutics. Specifically, Kite is collaborating with Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies.
Under the terms of the agreement, Sangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments, aggregated across 10 or more products utilizing Sangamo’s technology, based on the achievement of certain research, development, regulatory and successful commercialization milestones.
Essentially, Kite will use Sangamo’s ZFN technology to modify genes to develop next-generation cell therapies for autologous and allogeneic use in treating different cancers. Allogeneic cell therapies from healthy donor cells or from renewable stem cells would provide a potential treatment option that can be accessed directly within the oncology infusion center, thus reducing the time to infusion for patients.
We can look for an update on this collaboration in the report coming out late on Tuesday.
Over the past 52 weeks, Gilead has underperformed the broad markets, with its stock up about 5%. In just 2018 alone, the stock is only up about 1%.
A few analysts weighed in on Gilead ahead of the earnings report:
- Credit Suisse has a Hold rating with an $80 price target.
- Barclays has an Overweight rating and a $95 price target.
- RBC has a Buy rating with a $94 target price.
- Leerink Swann has a Market Perform rating with an $80 target.
- Mizuho has a Buy rating and a $95 price target.
Shares of Gilead were last seen trading at $72.02, with a consensus analyst price target of $89.05 and a 52-week range of $63.76 to $89.54.
24/7 Wall St.Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.